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The in vitro dissolution rates of prednisolone from five commercially available 5-rag prednisolone 
tablets were determined in distilled water. The dissolution studies were repeated on the fastest- and 
slowest-dissolving brands using 0.01% polysorbate 80 in 0.I N HCl as the dissolution medium. 
A two-way crossover bioavailability study was performed in i2 human male adult volunteers 
comparing the fastest- and slowest-dissolving brands. The plasma samples were assayed for pred- 
nisolone by a radioimmunoassay method. Statistical analysis of the data for the two brands showed 
no significant differences between average plasma levels of prednisolone at any sampling time. 
The results suggest that on the average the in vivo rates of dissolution of the two brands were 
essentially the same, and in vitro dissolution in 0.01% polysorbate 80--0.1 N HCI medium was 
better correlated with these in vivo results than dissolution in water. 
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I N T R O D U C T I O N  
Recently,  the A d  H o c  C o m m i t t e e  on  D r u g  P r o d u c t  Select ion of  the  
A c a d e m y  of  Gene ra l  P rac t i ce  of  P h a r m a c y  and  the A c a d e m y  of  P h a r m a c e u -  
t ical  Sciences has  inc luded  p r edn i so lone  on its list of  drugs  with high r isk 
po ten t i a l  for t he rapeu t i c  inequiva lence  due  to differences in b ioava i l ab i l i t y  
(1). P rev ious  s tudies  in m a n  (2,3) r equ i red  tha t  large doses of  p r e dn i so lone  
be given due to the  lack  of  sensi t ivi ty  in the  exist ing assay  methods .  The  
d e v e l o p m e n t  of  the  r a d i o i m m u n o a s s a y  for this s te ro id  has  a l lowed  the 
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determination of plasma levels after the administration of a single, low dose 
of prednisolone. 
This study employs the radioimmunoassay in the determination of 
the bioavailability of two brands of prednisolone. 
E X P E R I M E N T A L  
In Vitro Rate of  Dissolution Studies 
The dissolution apparatus consisted of a three-necked round-bot tom 
1000-ml flask suspended in a constant-temperature bath maintained at 
37 + I~ The dissolution medium was stirred at 50 + 3 rpm with a stirrer 
blade described by Wagner (4) using a standard servodyne power drive 
system. Fluid was continuously circulated through a small syringe barrel 
fitted with glass wool and small glass beads (one end of the barrel being 
immersed in the dissolution medium) into 0.29 cm ID silicone tubing, 
through a quartz flow cell in a Beckman DU spectrometer, then through 
a variable-speed Masterflex pump 4 and back into the dissolution flask. 
The dissolution medium was circulated at a rate of 70 ml/min. A V-shaped 
glass tube filled partially with glass beads was placed in the silicone tubing 
line to act as a debubbling device. A 10 mm path length flow cell was employed. 
The absorbance of the filtered dissolution medium was read continuously 
on a Gilford 2400 spectrophotometer chart recorder at 248 nm. 
Before each experimental run, the entire system was allowed to come 
to equilibrium. At zero time, a single tablet was dropped through one of the 
side openings of the three-necked dissolution flask so that it ultimately 
rested at the bot tom of the flask beneath the stirring blade. The absorbance 
was read continuously until greater than 75 % of the prednisolone had 
dissolved, at which time the circulation of dissolution medium was stopped 
and the stirring speed was increased to 200 rpm. After 30 rain, the stirring 
speed was reduced to 50 rpm and the circulation of fluid through the 
cell restored. This was repeated until a constant absorbance value was 
obtained. 
Deionized water was used as the dissolution medium in the first series 
of dissolution studies. A second series was performed using 0.01% polysor- 
bate 80 in 0.1 N hydrochloric acid as the dissolution medium (5). Tablets 
A, B, C, D, and E 5 were used in the first dissolution study, but only tablets 
A and B were studied in the second. 
4Cole-Parmer, Chicago, IU. 
STablet A was Meticortelone, 5 rag (Schering Corp.), Lot No. 1ACC1P35944; tablet B was 
Sterane, 5 rag (Pfizer), Lot No. 14424; tablet C was Ulacort, 5 rag (Fellows Testagar), Lot No. 
71628; tablet D was Delta-Cortef, 5mg (Upjohn), Lot No. 301AR-A2; and tablet E was 
Prednis, 5 mg (USV Pharmaceutical Corp.), Lot No. 50492. 
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Prednisolone powder 6 was used to calibrate the recorder. The absorb- 
ance value, corrected for baseline shifts, at "infinite" time was used as the 
value for 100 % steroid in solution. 
Subjects 
Twelve adult male volunteers between the ages of 23 and 39 years, 
weighing between 144 and 219 lb, and in good health were selected. Each 
subject received a medical history and physical examination. Values for 
the following tests were required to be within the normal range: hematocrit, 
white count, differential, SGOT, alkaline phosphatase, total bilirubin, serum 
creatinine, plasma 17-OHCS, electrocardiogram, and chest X-ray. 
Each subject selected received no barbiturates or other enzyme-inducing 
agents for a period of 30 days preceding the study and none concurrent with it. 
They received no other medication or alcoholic beverages for a period 
beginning 7 days preceding the study until completion of the study. 
The subjects were ordered so that the average body weights of subjects 
I, 2, 3, 10, 11, and 12 were about the same as the average body weights of 
subjects 4, 5, 6, 7, 8, and 9. 
Protocol 
Subjects fasted overnight and for 4 hr after administration of each dose 
of prednisolone. On the mornings when medication was administered, 
each subject drank 8 fluid ounces of water within the first hour after arising. 
No other food or beverage was taken until 4 hr after dosing with prednisolone. 
From 4 hr after dosing with prednisolone, food and beverage were taken 
ad libitum. 
Fifty milliliters of whole blood was taken from a forearm vein just 
before dosing with prednisolone at 0 time, and 10 ml of whole blood was 
taken at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hr after dosing with prednisolone. 
The !arge initial blood sample was collected in a syringe and transferred to 
a heparinized tube. The 10-ml blood samples were drawn into Vacutainer 
tubes containing heparin as the anticoagulant. Each sample of blood was 
centrifuged as soon as possible after collection, and the plasma was placed 
in a vial, stoppered, and labeled immediately. The plasma samples were then 
quick-frozen and stored in the frozen state until just prior to assay. 
Treatments and Schedules 
At 11:00PM on day minus one ( -1)  of each treatment period, each 
subject took orally 1.0rag of dexamethasone 7 to suppress endogenous 
secretion of hydrocortisone, 
6Sigma Chemical Co. 
7Given as two tablets of Decadron (MSD), 0.5 mg. 
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Table I. Treatment Schedules 
Phase 1 Phase I1 
Subjects Group (week 1) (week 2) 
1,2,3 I A B 
4,5,6 II B A 
7, 8, 9 III B A 
10, 11, 12 IV A B 
At plus 8 hr on day 1 (i.e., 8 hr after prednisolone administration) of 
each treatment period, each subject took 0.5 mg of dexamethasone 8 orally. 
On each phase of the crossover, each subject ingested orally 10 mg of 
prednisolone as two 5-mg tablets of tablet A or tablet B. The tablets were 
swallowed whole, not fractured or chewed before being swallowed. They 
were taken in the morning (about 8 AM) with 6 fluid ounces of water. The 
two doses were separated by a 1-week period. 
Both brands chosen had been purchased on the open market by the 
Food and Drug Administration and the tablets had passed the official tests 
including average potency and tablet-to-tablet uniformity tests in the 
laboratories of the Food and Drug Administration. 
The treatment schedules are shown in Table I. 
Assay of  Plasma Samples 
Plasma samples were assayed using a radioimmumoassay for predni- 
solone. The antiserum was developed by Colburn and Buller (6), but their 
assay procedure has been greatly modified to suit our needs. 
Each plasma sample had to be diluted with deionized water so that 
the binding of the tritiated prednisolone in the sample was in the most 
sensitive portion of the binding curve. This dilution factor was determined 
empirically. For this study, it was found that three distinct dilutions were 
required" 1:50 for the 1-, 2-, and 3-hr samples, 1:25 for the 88 89 4-, 6-, and 
8-hr samples, and 1:2 for the 12- and 24-hr samples. Individual samples 
often varied within this grouping. 
The drug in 1 ml of the appropriate sample dilution was extracted 
with 7 ml of methylene chloride, shaken for 5 min, and centrifuged for 5 min. 
The aqueous layer was removed and a 5-ml aliquot of the organic layer 
transferred to a disposable glass culture tube. The extract was evaporated 
to dryness at 37~ under a gentle stream of nitrogen gas. 
Fifty microliters of absolute ethanol was allowed to wash down the 
sides of the dried culture tubes to aid solution. This was followed by 1.0 ml 
of phosphate-buffered saline (7). This mixture was rapidly mixed on a 
SGiven as one tablet of Decadron (MSD), 0.5 mg. 
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vortexer for 1 min to insure the complete dissolution of the steroid. Ten 
microliters of tracer stock solution and 10/11 of undiluted antiserum were 
added and gently mixed. This solution was incubated for 2 hr at 37~ in 
a shaking water bath. 
At the end of the incubation period, the samples were immediately 
placed in an ice bath and 0,5 ml of cold dextran-coated charcoal suspension 
was added. Dextran-coated charcoal suspension consisted of 125rag 
Dextran T709 and 5.0 g charcoal 1~ in 100 ml of pH 7.4 phosphate-buffered 
saline solution. After gentle mixing, this suspension was immediately 
centrifuged at 1500 x g for 20 rain at 4~ The supernatant liquid was then 
added to 10 ml Unogel 11 liquid scintillation fluid. During the time between 
centrifugation and separation, the samples were kept in the ice bath. All 
samples were allowed to dark-adjust for at least 30 rnin before counting 
for 10 min in a Packard Tri-Carb liquid scintillation spectrophotometer. 
Each plasma sample was assayed in duplicate. 
A calibration curve was prepared by ass~iying samples of diluted blank 
(0 hr) plasma to which 1, 2, 4, 6, 10, and in some cases 14 ng of prednisolone 
had been added. In all cases, the dilutions of the blank plasma were the 
same as those of the samples and the blank plasma was that of the same 
subject whose prednisolone blood levels were being measured. 
With each calibration curve, the following "controls"  were included : 
1. A blank to which no antiserum had been added. This measured the 
"background"  radiation of the system. 
2. A sample which contained only radioactive prednisolone (i.e., no 
"cold"  drug). This measured the extent of the binding by the antiserum 
to the drug and was used as the "100 % bound"  term. 
3. A sample in which the radioactive drug had been added directly to 
the scintillation cocktail. This measured the total radioactivity 
initially in the system. 
Since this assay measures the amount  of tritiated prednisolone bound 
by the antiserum, the "percent bound"  was calculated as follows : 
Percent bound = sample reading - background reading x 100 
total count - background reading 
A sample calibration curve is shown in Fig. 1. All calibration curves were 
fitted essentially perfectly by the N O N L I N  program on an IBM 360/67 
computer to a biexponential equation. The amount  of drug in the experimen- 
tal samples was then determined by an iterative program on a Hewlett- 
Packard 9100A calculator. 
9Pharmacia Fine Chemicals, Uppsala, Sweden. 
1~ A, Sigma Chemical Co., St. Louis, Mo. 
I1Schwarz/Mann, Mountain View Ave., Orangeburg, N.Y. 
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Fig. 1. Sample calibration curve for the radioimmunoassay 
of prednisolone. 
RESULTS AND DISCUSSION 
In Vitro Rate of  Dissolution Studies 
Figures 2 and 3 are plots of the dissolution data for tablets A, B, C, D, 
and E in deionized water. Each point corresponds to the average percent 
dissolved of four tablets of each lot. Clearly, tablets A and B represent the 
extremes in dissolution rates among the tablets tested. Therefore, tablets 
A and B were selected as the treatments for the in vivo bioavailability study. 
Tablet A is also the innovator 's product. 
The dissolution studies were repeated on tablets A and B using 0.01% 
polysorbate 80 in 0.1 N hydrochloric acid as the dissolution medium. Table II 
and Fig. 4 compare the effects of these two dissolution media on these 
tablets. Two way analysis of variance of T25 v. and Tso vo values indicated 
that the dissolution rates of the two brands were significantly different. 
The tablet dissolution rates in each dissolution medium were also significantly 
different (p < 0.001 in all cases). 
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Fig. 2. In vitro dissolution of tablets A (O) and B ( I )  in deionized water. 
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I t I I I 
4 6 O 10 12 ~4 ~6 
TIM[ ( Mini/ 
Fig. 3. In vitro dissolution of three commercial 5-mg pred- 
nisolone tablets in deionized water: tablet C (me), tablet D (~), 
and tablet E (O). 
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Table II. Summary  of  the Effect of  the Dissolution Media on 
the Times Required to Dissolve 25, 50, and 7 5 ~  of the 
Prednisolone in the Tablets" 
Time (min), to 
dissolve indicated percentage of drug 
0.1 y HC1-0.01 ~o 
Distilled water polysorbate 80 
Treatment  A 
T25 Z 1.7 + 0.3 2.3 _+ 0.7 
T507. 3.0 _+ 0.5 4.4 _+ 0.7 
TTs7. 4.75 _+ 1.0 6.9 -t- 1.1 
Treatment  B 
T25 ~ 10.0 _+ 2.4 4.4 _+ 0.4 
Tso ~ 39.9 +_ 11.4 9.8 _+ 1.4 
Tv57. >100  >17  
"Each value represents average of four trials +_ SD. 
Plasma Concentrations 
The cross-reactivity of prednisolone and cortisol with the antiserum 
was found to be similar to that reported by Colburn and Buller (6). In order 





4 8 12 16 ' 20 24 
TIME IN MINUTES 
Fig. 4. Effect of dissolution media on the in vitro 
dissolution of tablets A (O) and  B ( a ) .  Dotted lines 
indicate deionized water as the dissolution medium. 
Solid lines indicate the 0,01~o polysorbate 80 in 
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suppress the adrenal secretion of cortisol. This was accomplished by admin- 
istering dexamethasone on the evening before and the afternoon of the 
day of the study. Dexamethasone, even in high concentrations, does not 
interfere with the binding of prednisolone to the antibody. 
The plasma concentrations of prednisolone measured in each phase of 
the crossover study are shown in Tables III and IV. Each point is the average 
of duplicate samples whose values have been computed from the least- 
squares fit of the calibration curve as described previously. 
Table V summarizes the treatment averages for the prednisolone study. 
There are no significant differences (p > 0.05) between average plasma 
concentrations at each sampling time, in peak plasma concentrations, areas 
under the plasma-level curves (both 0-12hr and 0-24hr), or half-lives. 
This indicates no significant difference in bioavailability of these two 
products. 
CONCLUSIONS 
The desirability of correlations of variables derived from in vitro 
dissolution rates with variables derived from in vivo testing in human 
Table V. Summary  of Results of  12-Subject Two-Way Crossover Prednisolone Study 
Plasma concentrat ions (ng/ml) : 
averages for 
Time (hr) Trea tment  A Treatment  B p value" 
0.25 63.4 33.1 0.10 < p < 0.25 
0.5 154 134 >0.25 
1 230 199 0.10 < p < 0.25 
2 207 211 >0.25 
3 188 210 0.10 < p < 0.25 
4 154 164 > 0.25 
6 86.6 90.0 > 0.25 
8 46.7 52.6 > 0.25 
12 20.0 19.2 >0.25 
24 3.63 6.54 0,05 < p < 0.10 
Other  parameters  
Peak plasma concentrat ion b (ng/ml) 248 243 > 0.25 
Area 0-12 hr ( n ~ l )  x hr  1224 1250 >0,25 
 roa0 ) x hr 1363 1405 >0.25 
Half-life (hr) 3.27 2.55 > 0.25 
"The p value is the significance level of the t reatment  mean  square from the analysis of variance 
for crossover design. 
bThe average of observed peak plasma levels of individual subjects. 
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volunteers is well established in biopharmaceutics (8). In this study, the 
results suggest that the in vivo rates of dissolution of tablets A and B are on 
the average the same. Based on this information, the in vitro dissolution in 
0.01 7o polysorbate 804).1 N hydrochloric acid medium correlates much 
better with the in vivo data than dissolution in water alone. 
Finholt and Solvang (5) have used similar polysorbate 80-hydrochloric 
acid dissolution medium to explore the role of surface tension on dissolution 
rates. They have shown that dissolution of phenacetin and phenobarbital 
powder in these systems mimics dissolution in diluted gastric juice. The 
present data demonstrate the improvement of in vivo-in vitro correlations 
obtained by taking into account the surface tension of physiological fluids. 
It is interesting that while the dissolution rate of tablet B increased 
dramatically in the second dissolution medium, the dissolution rate of 
tablet A was slightly slower. The dissolution of tablet A was still rapid and 
complete, so the cause of this phenomenon was not investigated. If some 
tableting ingredient is responsible for this change, it could significantly alter 
the in vivo dissolution of another tablet formulation while being undetectable 
with an in vitro dissolution test using water as the medium. Further investiga- 
tion into this matter may be warranted. 
Based on the data presented, it would be difficult to speculate on the 
bioavailability of tablets C, D, and E without further experimentation. 
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